Document is current
Any future updates will be listed below
-
Authors
Rautenberg, Christina
Middeke, Jan Moritz https://orcid.org/0000-0003-3250-293X
Röllig, Christoph https://orcid.org/0000-0002-3791-0548
Stelljes, Matthias https://orcid.org/0000-0002-9331-5145
Gaidzik, Verena https://orcid.org/0000-0001-6530-3406
Kriege, Oliver
Verbeek, Mareike
Koch, Katrin https://orcid.org/0000-0003-4664-8016
Unglaub, Julia Marie
Thol, Felicitas https://orcid.org/0000-0001-5848-6152
Krause, Stefan W. https://orcid.org/0000-0002-5259-4651
Hänel, Mathias
Neuerburg, Charlotte https://orcid.org/0009-0009-3134-9567
Vucinic, Vladan https://orcid.org/0000-0002-8398-285X
Jehn, Christian-Friedrich
Wass, Maxi
Heuser, Michael https://orcid.org/0000-0001-5318-9044
Fransecky, Lars
Chemnitz, Jens
Holtick, Udo
Schäfer-Eckart, Kerstin
Schröder, Josephine
Kraus, Sabrina
Krüger, William
Kaiser, Ulrich
Scholl, Sebastian
Kobbe, Guido https://orcid.org/0000-0002-9745-8813
Jäger, Paul Sebastian
Alakel, Nael https://orcid.org/0000-0003-3669-5564
von Bonin, Malte https://orcid.org/0000-0002-3828-0031
Sockel, Katja https://orcid.org/0000-0003-1732-7299
Hanoun, Maher https://orcid.org/0000-0002-1754-8940
Platzbecker, Uwe
Holderried, Tobias A. W. https://orcid.org/0000-0002-2474-523X
Morgner, Anke
Sauer, Tim
Götze, Katharina S. https://orcid.org/0000-0002-6276-8002
Wagner-Drouet, Eva https://orcid.org/0000-0002-0728-2253
Döhner, Konstanze https://orcid.org/0000-0002-2261-9862
Döhner, Hartmut https://orcid.org/0000-0003-2116-5536
Schliemann, Christoph https://orcid.org/0000-0003-1755-9583
Schetelig, Johannes https://orcid.org/0000-0002-2780-2981
Bornhäuser, Martin
Germing, Ulrich
Flossdorf, Sara https://orcid.org/0000-0003-0642-7104
Schroeder, Thomas https://orcid.org/0000-0002-1653-7959
Stölzel, Friedrich https://orcid.org/0000-0003-0653-5332
-
Funding
Funding for this research was provided by:
Jazz Pharmaceuticals
- License Information
-
More Information
Article History
Received: 7 January 2025
Revised: 11 March 2025
Accepted: 28 March 2025
First Online: 8 April 2025
Competing interests
: Thomas Schroeder: Advisory Board with honoraria: JAZZ Pharmaceuticals; lecture fees: JAZZ Pharmaceuticals; Reasearch Funding: JAZZ Pharmaceuticals. Jan Moritz Middeke: Consultancy work: Janssen, Roche, Gilead, Abbvie, JAZZ Pharmaceuticals, Pfizer, Astellas, Novartis, AstraZeneca, Glycostem; Shareholdings: Cancilico; Synagen; Honoraria: Novartis, Roche, Janssen, Abbvie, Pfizer, Sanofi, Astellas, Beigene: Reasearch Funding: JAZZ Pharmaceuticals, Janssen, Novartis; Financial travel support: Beigene. Friedrich Stölzel: Advisory Board with honoraria: JAZZ Pharmaceuticals, medac, Pierre Fabre, Servier, Astellas, Travel Support: Johnson & Johnson and Servier; Reasearch Funding: JAZZ Pharmaceuticals. Christina Rautenberg: Advisory Board with honoraria: BMS/Celgene Deutschland GmbH, Servier; Lecture fees: JAZZ Pharmaceuticals, BMS/Celgene Deutschland GmbH, Pfizer; Financial travel support: JAZZ Pharmeceuticals, BMS/Celgene Deutschland GmbH, medac; Reasearch Funding: JAZZ Pharmaceuticals. Hartmut Döhner: Advisory Board with honoraria: AbbVie, AstraZeneca, Gilead, Janssen, Jazz, Pfizer, Servier, Stemline, Syndax; Clinical Research Funding to Institution: AbbVie, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Servier; financial travel support: Abbvie, Servier. Katharina Götze: Advisory Board with honoraria: AbbVie, JAZZ, BMS/Celgene Deutschland GmbH, Alexion; research funding: BMS/Celgene. Tim Sauer: Advisory Board with honoraria: AbbVie, Takeda, Astellas. Guido Kobbe: received lecture fees from BMS/Celgene Deutschland GmbH, Novartis, Jazz Pharmaceuticals and Janssen-Cilag GmbH. Ulrich Germing: research funding: BMS/Celgene Deutschland GmbH, Novartis. Christoph Schlimann: Advisory Board with honoraria: AbbVie, Astellas, AstraZeneca, BMS/Celgene Deutschland GmbH, Laboratories Delbert, JAZZ Pharmaceuticals, Novartis, Otsuka, Pfizer, Roche; Research support (institutional): JAZZ Pharmaceuticals; financial travel support: AbbVie, BMS/Celgene Deutschland GmbH, JAZZ Pharmaceuticals, Pfizer. Verena I. Gaidzik: Advisory Board with honoraria: Jazz Pharmaceuticals, Abbvie, Boehringer-Ingelheim; Speakers Bureau: Pfizer, Janssen, Abbvie, Otsuka; Travel Support: Abbvie, JAZZ Pharmaceuticals. Stefan W. Krause: Lecture fees: Eickeler, expenses for meetings: Abbvie, JAZZ Pharmaceuticals, Alexion. Vladan Vucinic: Advisory Board with honoraria from Novartis, BMS/Celgene Germany GmbH, Takeda, Abbvie, Gilead/Kite, J&J. Felicitas Thol: Advisory Board with honoraria: BMS/Celgene Germany GmbH, Novartis, AbbVie, Menarini, Rigel; Lecture fees: AbbVie, Astellas. Julia Marie Unglaub: Financial travel support: JAZZ Pharmaceuticals and AbbVie.
: Treatment, monitoring and response assessment of the patients followed local guidelines of the respective centers which themselves are adapted from international guidelines, e.g. European Leukemia Net Recommendations. The study was approved by the ethics committee of the Heinrich-Heine-University, Duesseldorf (approval number: 2020–877) and all patients gave written informed consent for scientific use of their data.
